DE69616795D1 - Formulierungen mit gesteuerter freisetzung für schwerlösliche arzneistoffe - Google Patents

Formulierungen mit gesteuerter freisetzung für schwerlösliche arzneistoffe

Info

Publication number
DE69616795D1
DE69616795D1 DE69616795T DE69616795T DE69616795D1 DE 69616795 D1 DE69616795 D1 DE 69616795D1 DE 69616795 T DE69616795 T DE 69616795T DE 69616795 T DE69616795 T DE 69616795T DE 69616795 D1 DE69616795 D1 DE 69616795D1
Authority
DE
Germany
Prior art keywords
core
formulation
tablets
slave
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69616795T
Other languages
English (en)
Other versions
DE69616795T2 (de
Inventor
Joseph Clancy
Iain Cumming
Michael Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Application granted granted Critical
Publication of DE69616795D1 publication Critical patent/DE69616795D1/de
Publication of DE69616795T2 publication Critical patent/DE69616795T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69616795T 1995-07-03 1996-07-01 Formulierungen mit gesteuerter freisetzung für schwerlösliche arzneistoffe Expired - Fee Related DE69616795T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE950492A IE80467B1 (en) 1995-07-03 1995-07-03 Controlled release formulations for poorly soluble drugs
US89795P 1995-07-06 1995-07-06
PCT/IE1996/000039 WO1997002017A1 (en) 1995-07-03 1996-07-01 Controlled release formulations for poorly soluble drugs

Publications (2)

Publication Number Publication Date
DE69616795D1 true DE69616795D1 (de) 2001-12-13
DE69616795T2 DE69616795T2 (de) 2002-08-08

Family

ID=26319833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69616795T Expired - Fee Related DE69616795T2 (de) 1995-07-03 1996-07-01 Formulierungen mit gesteuerter freisetzung für schwerlösliche arzneistoffe

Country Status (20)

Country Link
EP (1) EP0836475B1 (de)
JP (1) JPH11508587A (de)
KR (1) KR19990028693A (de)
AT (1) ATE208192T1 (de)
AU (1) AU700654B2 (de)
BG (1) BG102228A (de)
BR (1) BR9609663A (de)
CA (1) CA2226008A1 (de)
CZ (1) CZ413497A3 (de)
DE (1) DE69616795T2 (de)
HU (1) HUP9900231A2 (de)
IE (1) IE80467B1 (de)
IL (1) IL122663A0 (de)
NO (1) NO975872L (de)
NZ (1) NZ311145A (de)
PL (1) PL324402A1 (de)
SK (1) SK175997A3 (de)
TW (1) TW426528B (de)
WO (1) WO1997002017A1 (de)
ZA (1) ZA965609B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283029B1 (it) * 1996-05-17 1998-04-03 Resa Farma Composizioni farmaceutiche a base di diclofenac
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
EP0866707A1 (de) * 1995-12-01 1998-09-30 Janssen Pharmaceutica N.V. Verzögerte freisetzung von cisapride
JP2001507359A (ja) * 1997-01-03 2001-06-05 エラン コーポレーション ピーエルシー 徐放性シサプリドミニ錠剤製剤
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US6312724B1 (en) 1997-04-04 2001-11-06 Isa Odidi Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
EP0966269A1 (de) * 1997-10-07 1999-12-29 Fuiz Technologies Ltd. Rasch-freisetzende arzneiverabreichungsform
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
IE980115A1 (en) * 1998-02-16 2000-02-09 Biovail Internat Ltd Solubilizing delivery systems and method of manufacture
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
EP1003485A1 (de) * 1998-06-11 2000-05-31 Em Industries, Inc. Mikroosmotisches gesteuertes arzneistoffabgabesysteme
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
IE981008A1 (en) * 1998-12-02 2000-06-14 Fuisz Internat Ltd Microparticles Containing Water Insoluble Active Agents
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1064938A1 (de) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
KR100379299B1 (ko) * 2000-01-15 2003-04-10 주식회사 중외제약 펠로디핀의 가용화 방법 및 방출제어형 제제
CA2444116C (en) * 2001-05-03 2009-01-20 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR20040011248A (ko) * 2002-07-30 2004-02-05 환인제약 주식회사 암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20050163839A1 (en) * 2003-01-29 2005-07-28 Sun Pharmaceutical Industries Limited Oral controlled release pharmaceutical composition containing metaxalone as active agent
WO2004069180A2 (en) 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
WO2004084870A1 (en) * 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
MXPA06005461A (es) * 2003-11-13 2006-12-15 Johnson & Johnson Dispersiones de mezclas en estado fundido que comprenden un farmaco de baja solubilidad en agua y un copolimero de bloque de oxido de etileno-oxido de propileno.
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
CA2548376A1 (en) 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
KR100598326B1 (ko) 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
ZA200806138B (en) * 2005-12-16 2009-11-25 Hanmi Pharm Ind Co Ltd Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
US20100038816A1 (en) 2006-08-16 2010-02-18 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
EP2142175A2 (de) * 2007-03-30 2010-01-13 Wockhardt Research Centre Pharmazeutische zusammensetzungen aus diclofenac und misoprostol
ES2400964T3 (es) 2007-04-04 2013-04-15 Sigmoid Pharma Limited Composiciones famacéuticas de ciclosporina
WO2008132707A1 (en) 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
BRPI1014272A2 (pt) 2009-04-24 2016-10-18 Iceutica Pty Ltd nova formulação de diclofenac
CN102470106B (zh) 2009-05-18 2015-09-23 希格默伊德药业有限公司 包含油滴的组合物
IN2012DN00781A (de) 2009-08-12 2015-06-26 Sigmoid Pharma Ltd
FR2967576B1 (fr) * 2010-11-18 2013-07-12 Advicenne Pharma Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament
FR2967577B1 (fr) * 2010-11-18 2013-07-12 Advicenne Pharma Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN102784128B (zh) * 2012-07-31 2015-01-07 北京协和药厂 一种非洛地平缓释制剂及其制备方法
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
ES2858517T3 (es) 2014-11-07 2021-09-30 Sublimity Therapeutics Ltd Composiciones que comprenden ciclosporina
WO2019220282A1 (en) * 2018-05-14 2019-11-21 Capsugel Belgium Nv Solid dosage forms with high active agent loading

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2037179T3 (es) * 1987-11-25 1993-06-16 American Cyanamid Company Sistema de liberacion sostenida (controlada) para bloqueadores de canales de calcio de dihidropiridina.

Also Published As

Publication number Publication date
WO1997002017A1 (en) 1997-01-23
CA2226008A1 (en) 1997-01-23
NO975872L (no) 1998-03-03
IE80467B1 (en) 1998-07-29
JPH11508587A (ja) 1999-07-27
ZA965609B (en) 1997-01-27
BG102228A (en) 1998-10-30
HUP9900231A2 (hu) 1999-06-28
MX9710413A (es) 1998-07-31
TW426528B (en) 2001-03-21
ATE208192T1 (de) 2001-11-15
AU700654B2 (en) 1999-01-14
AU6239496A (en) 1997-02-05
EP0836475B1 (de) 2001-11-07
NZ311145A (en) 1999-06-29
EP0836475A1 (de) 1998-04-22
CZ413497A3 (cs) 1998-04-15
DE69616795T2 (de) 2002-08-08
KR19990028693A (ko) 1999-04-15
SK175997A3 (en) 1998-06-03
IL122663A0 (en) 1998-08-16
NO975872D0 (no) 1997-12-12
BR9609663A (pt) 1999-05-18
PL324402A1 (en) 1998-05-25

Similar Documents

Publication Publication Date Title
DE69616795D1 (de) Formulierungen mit gesteuerter freisetzung für schwerlösliche arzneistoffe
ATE232090T1 (de) Orale pharmazeutische zusammensetzungen die pantoprazol mit verzögerter freisetzung und antimikrobielle mittel enthalten
DE3872739T2 (de) Arzneimittel mit langsamer freisetzung.
MY100721A (en) Therapeutic agent.
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
DK0939626T3 (da) Galenisk form til forlænget frigivelse af milnacipran
DK0923934T3 (da) Modified release-matrixformulering af cefaclor og cephalexin
ATE430561T1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
CA2000932A1 (en) Oral pharmaceutical controlled release multiple unit dosage form
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
WO2001013898A3 (en) Pharmaceutical formulations with different release times
DE60006362D1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
ATE212840T1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
CA2307547A1 (en) Chronotherapeutic diltiazem formulations and the administration thereof

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ELAN CORP. PLC, DUBLIN, IE

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee